In our study, we assessed the impact of PEG-IFN/RBV on the gene expression profiles in PBMCs of patients with CH-C during treatment and analyzed these data according to their IL28B genotype status as well as their SVR outcome. This evidence concerns the gene IFNL3 and cyclic hematopoiesis.